Navigation Links
Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
Date:8/5/2008

t expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work the Company's employees were assigned to perform, totaled RMB6.4 million (US$0.9 million) for the second quarter of 2008. The share-based compensation expenses for the second quarter of 2007 were RMB7.7 million. For the first six months of 2008, share-based compensation expenses totaled RMB13.4 million (US$2.0 million), a decrease of 7.5% from RMB14.5 million for the first six months of 2007.

Operating income was RMB98.1 million (US$14.3 million) for the second quarter of 2008, representing an increase of 73.9% as compared to RMB56.4 million for the corresponding period of 2007. For the first six months of 2008, operating income was RMB197.3 million (US$28.8 million), an increase of 51.3% as compared to RMB130.5 million in the corresponding period in 2007.

Income tax expense for the second quarter of 2008 totaled RMB18.1 million (US$2.6 million) compared to an income tax credit of RMB4.0 million for the corresponding period of 2007. For the first six months of 2008, income tax expense was RMB34.9 million (US$5.1 million) compared to an income tax credit of RMB2.5 million for the first six months of 2007. In addition to the overall increase in taxable income, the increased income tax expense in 2008 was primarily due to the expiration of tax holidays enjoyed by two PRC subsidiaries.

Net income was RMB95.2 million (US$13.9 million) for the second quarter of 2008, compared to RMB83.1 million in the corresponding period a year ago and representing growth of 14.5%. The Company's net margin (net income as a percentage of total revenue) was 21.8% for the second quarter of 2008 compared to 24.9% for the second quarter of 2007. For the first six months of 2008, net income was RMB207.3 million (US$30.2 million), an increase of 38.1% as compared to RMB150.1 million for the first six months of 2007. Net margin for the first six mo
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
7. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
8. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
9. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... York, NY (PRWEB) , ... September 01, 2015 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced its annual Light it Red for Lymphoma awareness initiative, ...
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty Gives Back Art Team ... the Fashion” on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, on ... collaboration between fashion and professional hair, makeup and nail design. , The evening ...
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. has been stuck ... Money for Good 2015, released today by Camber Collective, goes to the root of ... mobilize up to $22B in new philanthropic giving and shift $25B that’s already being ...
(Date:9/1/2015)... ... 01, 2015 , ... Georgia State University and its partners ... in stemming sexual assaults on their campuses. , The free, evidence-based survey was ... assault researchers and student affairs professionals responding to calls by the Obama Administration ...
(Date:9/1/2015)... ... 01, 2015 , ... Consumers overwhelmingly prefer to have their ... according to a new survey that also offers insight on why that is ... which reflects views on cosmetic medical treatments and ratings for 10 specific procedures ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3
... 2008 (March 24), the Infectious Diseases Society of America ... U.S. policymakers to step up the fight against tuberculosis ... home and abroad. , With drug-resistant strains of TB ... on the decline, resources are needed to support TB ...
... OVERLAND PARK, Kan., March 20 A recent ... a strong reminder to,horse owners throughout the country ... mosquito-borne diseases. To ensure your horse receives,the most ... Nile-,Innovator(R)+EWT -- "The Mosquito Shot," the only vaccine ...
... Experience , KENNEBUNK, Maine, March 20 ... body care, announced a patent-pending breakthrough formula,in its ... Sensitive Care,Toothpastes., (Photo: http://www.newscom.com/cgi-bin/prnh/20080320/NETH004 ), ... cofounder & CEO of Tom,s of Maine, announced ...
... Dreier LLP (http://www.dreierllp.com ),announces that a ... District,Court for the District of Massachusetts on behalf ... the "Company"),(Nasdaq: VRTX ) publicly traded securities ... 2, 2007, inclusive (the "Class Period"). The,Complaint alleges ...
... Mass., March 20 Alseres,Pharmaceuticals, Inc. (Nasdaq: ... a,Third Amended and Restated Convertible Promissory Note Purchase ... L. Gipson, Thomas Gipson, Arthur,Koenig, Ingalls & Snyder ... "Purchaser"). The agreement provides for the Company to ...
... Response Biomedical,Corporation (TSX: RBM, OTCBB: RPBIF) today ... new state-of-the-art global headquarters located at 1781 ... March 31, 2008., The 46,000 square ... and constructed for development and GMP manufacturing,and ...
Cached Medicine News:Health News:ID, HIV experts urge more resources for TB 2Health News:Fort Dodge's 'Mosquito Shot' Offers Convenient Protection Against Dangerous Mosquito-Borne Illnesses 2Health News:Tom's of Maine Introduces a Patent-Pending New Formula with the Launch of its Natural Clean & Gentle Care and Sensitive Care Toothpastes 2Health News:Tom's of Maine Introduces a Patent-Pending New Formula with the Launch of its Natural Clean & Gentle Care and Sensitive Care Toothpastes 3Health News:Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX) 2Health News:Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX) 3Health News:Alseres Pharmaceuticals, Inc. Raises $5 Million 2Health News:Alseres Pharmaceuticals, Inc. Raises $5 Million 3Health News:Response Biomedical Corporation Moves to New Facility 2Health News:Response Biomedical Corporation Moves to New Facility 3Health News:Response Biomedical Corporation Moves to New Facility 4
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. Daniel K. ... Michael C. Burgess , M.D., and Joe ... st Century Cures Act, bipartisan legislation in support ... the United States Senate. UT ... department chairs, center directors, and leading researchers – joined ...
(Date:9/1/2015)... , Sept. 1, 2015   Alpha Imaging LLC , a ... Cleveland announced today that they have been awarded exclusive ... imaging systems in Michigan.   The new territory supplements Alpha Imaging,s existing ... including Ohio , Indiana , ... Maryland , West Virginia , ...
(Date:9/1/2015)... Taiwan,s GNT Biotech & Medicals ... Taipei on  August 25 th  to ... drug delivery technology that uses nano-scale gold as the ... a joint press conference held by its parent company ... latest edible gold-based food and beverage partners, together with ...
Breaking Medicine Technology:U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5Alpha Imaging Expands Shimadzu Territory 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: